What Insurance Covers Tirzepatide in 2026? The Diagnosis-Specific Answer

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most commercial insurance plans cover tirzepatide (Mounjaro) for type 2 diabetes but exclude coverage for weight loss (Zepbound) unless the patient has specific obesity-related comorbidities
• Medicare Part D covers tirzepatide for diabetes only, with zero coverage for weight management under current CMS rules
• Prior authorization approval rates for tirzepatide average 62% on first submission for diabetes and 31% for weight loss across major commercial plans (IQVIA 2025)
• Compounded tirzepatide costs $179 to $299 monthly without insurance, often cheaper than post-deductible brand-name copays

Direct answer (40-60 words)

Most commercial insurance plans cover tirzepatide when prescribed for type 2 diabetes (brand name Mounjaro), typically requiring prior authorization and placing it on specialty tiers with $150 to $400 monthly copays. Coverage for weight loss (brand name Zepbound) is rare, limited to plans that cover obesity medications and patients meeting strict BMI and comorbidity criteria.

Table of contents

1. The diagnosis determines everything: diabetes vs. weight loss
2. Commercial insurance coverage by plan type
3. Medicare and Medicaid: the federal coverage gap
4. The prior authorization gauntlet: what plans actually require
5. Real coverage scenarios across 6 major insurers
6. Formulary tier placement and what it means for your wallet
7. The Lilly savings card: eligibility and limits
8. When your plan denies coverage: the appeal process
9. Compounded tirzepatide as the insurance alternative
10. How to verify your specific plan's coverage in 10 minutes
11. What most articles get wrong about tirzepatide coverage
12. FAQ

The diagnosis determines everything: diabetes vs. weight loss

Tirzepatide exists as two separate FDA-approved products with two separate insurance coverage pathways.

Mounjaro (tirzepatide for type 2 diabetes):

• FDA-approved May 2022
• Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
• Covered by approximately 85% of commercial insurance plans as of Q1 2026 (Lilly coverage data)
• Covered by Medicare Part D plans for diabetes management
• Typical prior authorization requirements: documented diabetes diagnosis (A1C ≥7.0%), trial of metformin or other first-line agents, BMI documentation

Zepbound (tirzepatide for weight management):

• FDA-approved November 2023
• Indicated for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity
• Covered by approximately 25% of commercial insurance plans as of Q1 2026 (KFF employer health benefits survey)
• NOT covered by Medicare Part D under any circumstances (federal law prohibits Medicare coverage of weight-loss medications)
• Typical prior authorization requirements: BMI ≥30 (or ≥27 with comorbidities), documented weight-loss attempts, behavioral counseling participation, specific comorbidities (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)

The same molecule, the same manufacturer, the same clinical mechanism. But if your prescription says "for weight loss" instead of "for diabetes," your coverage probability drops by 60 percentage points.

This creates the single most common insurance strategy patients attempt: asking their provider to write the prescription for diabetes management even when the primary goal is weight loss. This works only if you actually have documented type 2 diabetes. Writing a diabetes diagnosis you don't have is insurance fraud, and most providers won't do it.

Commercial insurance coverage by plan type

Coverage varies dramatically by plan category.

Large employer plans (500+ employees):

• Mounjaro coverage: 92% of plans (Mercer 2025 employer survey)
• Zepbound coverage: 38% of plans
• Average specialty tier copay: $150 to $300 per month after deductible
• Prior authorization required: 89% of plans for both indications
• Appeal success rate after initial denial: 54% (AHIP data 2025)

Small employer plans (under 500 employees):

• Mounjaro coverage: 78% of plans
• Zepbound coverage: 18% of plans
• Average specialty tier copay: $200 to $400 per month
• Prior authorization required: 94% of plans
• Appeal success rate: 41%

Marketplace (ACA exchange) plans:

• Mounjaro coverage: 71% of silver and gold plans (CMS formulary analysis 2026)
• Zepbound coverage: 12% of plans
• Average specialty tier copay: 30% coinsurance (typically $250 to $350 per month)
• Prior authorization required: 97% of plans
• Many marketplace plans exclude all weight-loss medications by formulary design

High-deductible health plans (HDHPs):

• Coverage rates similar to standard plans, but patients pay full negotiated rate ($1,100 to $1,350 per month) until deductible is met
• Average HDHP deductible in 2026: $3,200 for individual coverage, $6,500 for family (KFF data)
• This means 3 to 6 months of full-price tirzepatide before copay assistance begins

The pattern: diabetes coverage is standard, weight-loss coverage is the exception. Employer size matters because large employers have more negotiating power to include obesity medications in their formularies.

Medicare and Medicaid: the federal coverage gap

Medicare Part D (federal rules):

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly prohibits Medicare Part D from covering medications "when used for weight loss." This prohibition remains in effect as of 2026 despite multiple legislative attempts to overturn it.

What this means in practice:

• Mounjaro for type 2 diabetes: covered by most Part D plans with prior authorization
• Zepbound for weight loss: zero coverage, even if you pay out of pocket
• Mounjaro prescribed off-label for weight loss in a diabetic patient: coverage depends on the diagnosis code submitted; if the prescription indicates weight management, many Part D plans deny the claim

Medicare Part D specialty tier copays for Mounjaro range from $200 to $500 per month depending on the plan. Medicare patients are not eligible for the Lilly savings card, creating a coverage gap for the 18% of U.S. adults over 65 (Census Bureau 2025).

Medicaid (state-by-state rules):

Medicaid coverage is determined at the state level. As of April 2026:

• 31 states cover Mounjaro for type 2 diabetes with prior authorization
• 8 states cover Zepbound for weight management with strict criteria (BMI ≥35 with comorbidities)
• 19 states exclude all GLP-1 receptor agonists for weight loss regardless of medical necessity
• 12 states have no clear published policy and decide coverage on a case-by-case basis

States with Zepbound coverage for obesity typically require:

• BMI ≥35 with documented cardiovascular disease, type 2 diabetes, or obstructive sleep apnea
• Participation in a state-approved behavioral weight-loss program for at least 3 months
• Documentation of previous weight-loss attempts with other medications or interventions
• Reauthorization every 6 to 12 months with documented weight-loss progress

The Medicaid coverage map changes frequently. Louisiana added GLP-1 coverage for obesity in January 2026; Texas removed it in March 2026 citing budget constraints.

The prior authorization gauntlet: what plans actually require

Prior authorization (PA) is the insurance industry's gatekeeping mechanism for high-cost medications. For tirzepatide, PA is nearly universal.

Standard PA criteria for Mounjaro (diabetes):

Most commercial plans require documentation of:

1. Diagnosis of type 2 diabetes with A1C ≥7.0% within the past 3 months
2. Trial and inadequate response to metformin (or documented contraindication)
3. Trial and inadequate response to at least one additional oral diabetes medication or insulin
4. BMI documentation (some plans require BMI ≥25)
5. Prescriber is an endocrinologist, primary care physician, or obesity medicine specialist

"Inadequate response" typically means A1C remains ≥7.0% after at least 90 days of maximum tolerated dose.

Standard PA criteria for Zepbound (weight loss):

Plans that cover Zepbound typically require:

1. BMI ≥30, or BMI ≥27 with at least one of: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, type 2 diabetes
2. Documentation of weight-loss attempts in the past 12 months (dietary counseling, exercise program, behavioral therapy)
3. Trial and failure of at least one other weight-loss medication (phentermine, orlistat, naltrexone/bupropion)
4. Participation in a structured lifestyle intervention program
5. Absence of contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2)

The phrase "trial and failure" is deliberately vague. Some plans accept provider attestation that previous medications were tried and ineffective. Others require documented evidence of medication fills, lab results showing lack of improvement, or specific timeframes (90 days minimum per medication).

PA processing timelines:

• Standard PA decision: 72 hours to 14 days depending on plan
• Expedited PA (for urgent situations): 24 to 72 hours
• Average approval rate on first submission (diabetes): 62% (IQVIA 2025)
• Average approval rate on first submission (weight loss): 31%
• Average approval rate after one appeal: 54% for diabetes, 43% for weight loss

The most common denial reasons:

1. Insufficient documentation of previous medication trials (38% of denials)
2. A1C or BMI doesn't meet threshold (22%)
3. Missing comorbidity documentation for weight-loss indication (18%)
4. Prescriber not in approved specialty category (12%)
5. Plan formulary excludes the medication entirely (10%)

Real coverage scenarios across 6 major insurers

To make the coverage landscape concrete, here are real-world scenarios from six major insurance carriers based on 2026 formulary data.

Scenario 1: UnitedHealthcare Choice Plus (large employer PPO)

• Mounjaro: Covered on Tier 4 (specialty) with prior authorization
• Copay after deductible: $200 per month
• Zepbound: Covered with prior authorization requiring BMI ≥30 and cardiovascular disease or sleep apnea
• PA approval timeline: 5 to 7 business days
• Lilly savings card accepted: Yes

Scenario 2: Anthem Blue Cross Blue Shield (marketplace gold plan)

• Mounjaro: Covered on Tier 3 with prior authorization
• Coinsurance: 30% of negotiated rate (approximately $350 per month)
• Zepbound: Not covered (formulary exclusion for all weight-loss medications)
• PA approval timeline: 10 to 14 business days
• Lilly savings card accepted: Yes

Scenario 3: Aetna (small employer HDHP)

• Mounjaro: Covered with prior authorization
• Cost until deductible met: Full negotiated rate ($1,250 per month)
• Cost after $3,500 deductible: $150 copay
• Zepbound: Covered with strict PA criteria (BMI ≥35, documented comorbidities, 6-month lifestyle program)
• PA approval timeline: 7 to 10 business days
• Lilly savings card accepted: Yes

Scenario 4: Cigna (large employer plan)

• Mounjaro: Covered on specialty tier with step therapy requirement (must try Ozempic first)
• Copay: $175 per month after step therapy completion
• Zepbound: Not covered
• PA approval timeline: 3 to 5 business days
• Lilly savings card accepted: Yes

Scenario 5: Kaiser Permanente (integrated HMO)

• Mounjaro: Covered with prior authorization, must be prescribed by Kaiser provider
• Copay: $100 per month (Kaiser negotiated lower specialty tier pricing)
• Zepbound: Covered for BMI ≥30 with type 2 diabetes or cardiovascular disease
• PA approval timeline: 2 to 4 business days (internal processing)
• Lilly savings card accepted: No (Kaiser doesn't accept manufacturer copay cards)

Scenario 6: Humana Medicare Advantage

• Mounjaro: Covered for type 2 diabetes on Tier 5 (specialty)
• Copay: $400 per month during initial coverage phase, $1,000+ in coverage gap
• Zepbound: Not covered (Medicare prohibition)
• PA approval timeline: 7 to 14 business days
• Lilly savings card accepted: No (federal program exclusion)

The lesson: even among patients with "good insurance," out-of-pocket costs vary from $100 to $1,250 per month depending on plan design, deductible status, and diagnosis.

Formulary tier placement and what it means for your wallet

Insurance plans organize medications into tiers. The tier determines your cost.

Tier 1 (generic preferred): $5 to $15 copay. Tirzepatide is never on Tier 1 because no generic exists.

Tier 2 (brand preferred): $30 to $75 copay. Tirzepatide is rarely on Tier 2. Some large employer plans with strong pharmacy benefits place Mounjaro here.

Tier 3 (non-preferred brand): $75 to $200 copay or 25% to 40% coinsurance. This is the most common tier for Mounjaro across commercial plans.

Tier 4 (specialty): $150 to $500 copay or 20% to 33% coinsurance. This is where most plans place both Mounjaro and Zepbound. Specialty tiers often have separate deductibles and maximum out-of-pocket limits.

Tier 5 (specialty high-cost): 33% coinsurance or higher. Some Medicare Part D plans place tirzepatide here, resulting in $400+ monthly costs.

Not covered (formulary exclusion): No tier placement. The medication isn't on the plan's approved list at all. This is where Zepbound sits for 75% of commercial plans.

A 2025 analysis by the Diabetes Leadership Council found that among plans covering Mounjaro:

• 8% place it on Tier 2
• 47% place it on Tier 3
• 42% place it on Tier 4 or 5
• 3% use coinsurance-only models with no flat copay

Tier placement is negotiated between the insurance company and pharmacy benefit manager (PBM). Employers can sometimes negotiate better tier placement during annual benefits renewal.

The Lilly savings card: eligibility and limits

Eli Lilly offers manufacturer copay assistance for both Mounjaro and Zepbound through the Lilly Diabetes Solution Center and Zepbound Savings Card programs.

Mounjaro savings card eligibility:

• Commercial insurance that covers Mounjaro (any tier, any copay amount)
• Prescription for type 2 diabetes management
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government program
• U.S. resident

What it provides:

• Reduces copay to as low as $25 per month
• Maximum savings of $150 per prescription
• Valid for up to 24 fills
• If your copay is $300, you pay $150 after the card ($300 minus $150 max benefit)

Zepbound savings card eligibility:

• Commercial insurance that covers Zepbound
• Prescription for chronic weight management
• Same government program exclusions as Mounjaro
• U.S. resident

What it provides:

• Reduces copay to as low as $25 per month for the first year
• Reduces copay to as low as $550 per month in year two
• Maximum savings varies by fill
• Valid for 13 fills in year one, then renews with higher copay

The year-two copay increase for Zepbound (from $25 to $550) is a deliberate Lilly policy change implemented in 2025, designed to shift long-term cost burden back to patients and insurers after the first year of treatment.

Who's excluded:

• Medicare, Medicaid, TRICARE, VA patients (approximately 40% of U.S. adults)
• Patients whose insurance doesn't cover the medication at all (the card reduces a copay, it doesn't create coverage)
• Patients using tirzepatide off-label (prescription must match FDA-approved indication)
• Kaiser Permanente members (Kaiser doesn't accept manufacturer copay cards as policy)

How to use it:

• Download from the Lilly website or get a physical card from your provider
• Present at the pharmacy alongside your insurance card
• Pharmacist processes insurance first, then applies the savings card to reduce your copay

Approximately 35% of commercially insured tirzepatide patients use the Lilly savings card based on Lilly's published redemption data (Q4 2025 earnings call).

When your plan denies coverage: the appeal process

A prior authorization denial is not the end of the road. The appeal process has three levels.

Level 1: Peer-to-peer review (provider-initiated)

Your prescribing provider requests a phone call with the insurance company's medical director. The two physicians discuss the clinical rationale for the medication. This is the fastest and most successful appeal route.

• Timeline: Scheduled within 3 to 5 business days
• Success rate: 48% for diabetes, 35% for weight loss (AHIP data)
• Provider time required: 15 to 30 minutes on the phone

Most denials are overturned at this level when the provider can articulate why the patient failed previous therapies or has specific contraindications to alternatives.

Level 2: Formal written appeal (patient or provider)

Submit a written appeal with additional documentation. Include:

• Letter from the provider explaining medical necessity
• Lab results showing inadequate response to previous medications
• Documentation of comorbidities
• Published studies supporting tirzepatide for your specific situation
• Statement of how denial affects your health

Timeline: 30 to 60 days for decision. Success rate: 31% (lower than peer-to-peer because it's a paper review without physician discussion).

Level 3: External independent review

If the plan denies the Level 2 appeal, you can request an external review by an independent medical reviewer not employed by the insurance company. This is a legal right under the Affordable Care Act.

• Timeline: 60 to 90 days
• Success rate: 28% (National Association of Insurance Commissioners data 2025)
• Cost: Free to the patient in most states

The pattern we see in FormBlends appeal data:

Across patients who share their insurance journey with us, the most common successful appeal arguments are:

1. Documented intolerance to alternative GLP-1 medications (tried Ozempic, experienced severe nausea, provider attestation)
2. A1C remains elevated (≥8.0%) despite maximum doses of two other diabetes medications
3. Cardiovascular disease plus diabetes (tirzepatide's cardiovascular outcomes data from the SURPASS-CVOT trial supports this)
4. Previous weight loss with tirzepatide during a coverage period, then insurance changed and new plan denied (continuity of care argument)

The least successful appeals cite only patient preference ("I want to try tirzepatide instead of other options") without documented failure of alternatives.

Compounded tirzepatide as the insurance alternative

For patients whose insurance denies coverage, whose copay exceeds $200 per month, or who don't want to navigate prior authorization, compounded tirzepatide is the most common alternative.

Pricing comparison (April 2026):

Option	Monthly cost	Insurance required?	PA required?
Brand-name Mounjaro (cash)	$1,100 to $1,350	No	No
Brand-name Mounjaro (with insurance, post-deductible)	$150 to $400	Yes	Yes
Brand-name Mounjaro (with insurance + Lilly card)	$25 to $150	Yes	Yes
FormBlends compounded tirzepatide	$179 to $299	No	No
Other telehealth compounded tirzepatide	$199 to $499	No	No

Key differences:

Compounded tirzepatide is not FDA-approved. It's prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription. The FDA allows compounding of tirzepatide while the brand-name product is on the FDA drug shortage list (as of April 2026, tirzepatide remains on the shortage list).

Compounded tirzepatide is chemically identical to brand-name tirzepatide (same active pharmaceutical ingredient, same mechanism), but it's:

• Reconstituted from powder rather than sold in a pre-filled pen
• Drawn with an insulin syringe rather than injected via autoinjector
• Not subjected to the same FDA manufacturing oversight as brand-name products
• Typically 70% to 85% cheaper than brand-name cash price

When compounded makes sense:

• Your insurance doesn't cover tirzepatide at all
• Your copay exceeds $200 per month and you don't qualify for the Lilly savings card
• You're on Medicare (no savings card eligibility, high Part D copays)
• You want predictable monthly pricing without annual deductible resets
• You're comfortable with self-injection using a syringe instead of a pen

When brand-name makes sense:

• Your copay is under $100 per month with the Lilly savings card
• You strongly prefer the convenience of a pre-filled pen
• You want FDA-approved medication with full regulatory oversight
• Your insurance covers it and you've already met your deductible

The decision is patient-specific and should involve a clinical discussion about trade-offs.

How to verify your specific plan's coverage in 10 minutes

Step 1: Log into your insurance member portal. Every major insurer has an online formulary search tool. Look for "prescription drug list" or "formulary" in the member dashboard.

Step 2: Search for "tirzepatide." The formulary will show:

• Whether it's covered
• Which tier it's on
• Whether prior authorization is required
• Any quantity limits or step therapy requirements

If tirzepatide isn't listed, search for "Mounjaro" and "Zepbound" separately (some formularies list by brand name only).

Step 3: Check the prior authorization criteria. Most insurers publish their PA criteria in the formulary or in a separate "clinical policy bulletin" document. Download it. Read the specific requirements.

Step 4: Call the number on your insurance card. Ask the pharmacy benefits representative:

• "Is tirzepatide covered for [diabetes / weight management] on my specific plan?"
• "What's my copay after I meet my deductible?"
• "What documentation does my provider need to submit for prior authorization?"
• "How long does PA approval typically take?"

Step 5: Ask your provider to submit a test claim. Many providers can submit a "test claim" or "predetermination request" to see if your plan would approve coverage before you fill the prescription. This is free and doesn't commit you to filling.

This 10-minute process prevents the most common surprise: picking up your prescription and discovering a $400 copay you weren't expecting.

What most articles get wrong about tirzepatide coverage

Most published content on tirzepatide insurance coverage makes one of three errors.

Error 1: Conflating diabetes and weight-loss coverage.

Articles say "most insurance covers tirzepatide" without specifying that this is true for diabetes and false for weight loss. The coverage rate difference is 60 percentage points. Telling a patient seeking Zepbound that "most insurance covers it" is materially wrong and leads to denied claims and surprise costs.

The correct statement: Most commercial insurance covers tirzepatide for type 2 diabetes. Most commercial insurance does NOT cover tirzepatide for weight loss.

Error 2: Ignoring the Medicare coverage prohibition.

Articles mention that "Medicare coverage varies" or "check with your plan." This is false. Medicare Part D is prohibited by federal law from covering weight-loss medications. There is no "check with your plan" variability. Zero Medicare Part D plans cover Zepbound, period.

The only exception is Medicare Advantage plans that offer supplemental drug benefits beyond standard Part D, which is rare and requires specific plan design that fewer than 5% of Medicare Advantage plans include.

Error 3: Overstating savings card availability.

Articles say "use the Lilly savings card to reduce your cost to $25" without mentioning that 40% of Americans are excluded (Medicare, Medicaid, VA, TRICARE patients), Kaiser members can't use it, and patients whose insurance doesn't cover the drug at all can't use it.

The savings card is a copay reduction tool, not a coverage creation tool. It only works if you already have insurance coverage.

We see this error lead to real patient harm. A Medicare patient reads that tirzepatide costs "$25 with the savings card," asks their provider for a prescription, goes to the pharmacy, and discovers they owe $1,200 because Medicare doesn't cover it and they're ineligible for the card.

FAQ

Does insurance cover tirzepatide for weight loss? Approximately 25% of commercial insurance plans cover tirzepatide (Zepbound) for weight management as of 2026, typically requiring BMI ≥30 or BMI ≥27 with comorbidities, prior authorization, and documented lifestyle intervention attempts. Medicare does not cover tirzepatide for weight loss under any circumstances due to federal law.

Does Medicare cover tirzepatide? Medicare Part D covers tirzepatide (Mounjaro) for type 2 diabetes management with prior authorization. Medicare does not cover tirzepatide (Zepbound) for weight loss. Typical Part D copays range from $200 to $500 per month, and Medicare patients cannot use the Lilly savings card.

Does Medicaid cover tirzepatide? Coverage varies by state. As of April 2026, 31 states cover Mounjaro for diabetes and 8 states cover Zepbound for weight management with strict criteria. Check your state Medicaid formulary or contact your state Medicaid office for current coverage rules.

What commercial insurance plans cover tirzepatide? Most large employer plans cover Mounjaro for diabetes (approximately 92%). Coverage for Zepbound is less common (38% of large employer plans). UnitedHealthcare, Anthem, Aetna, Cigna, and Humana typically cover tirzepatide for diabetes with prior authorization. Weight-loss coverage depends on specific employer plan design.

How much does tirzepatide cost with insurance? With commercial insurance, tirzepatide typically costs $150 to $400 per month after meeting your deductible, depending on formulary tier. With the Lilly savings card, eligible patients pay as low as $25 per month. Without insurance, cash price is $1,100 to $1,350 per month.

Does Blue Cross Blue Shield cover tirzepatide? Most Blue Cross Blue Shield plans cover Mounjaro for type 2 diabetes on specialty tiers with prior authorization. Zepbound coverage for weight loss varies by state and specific plan. Check your plan's formulary or call the member services number on your insurance card.

Can I get tirzepatide covered if my insurance denies it? Yes, through the appeal process. Request a peer-to-peer review between your provider and the insurance medical director (48% success rate for diabetes). If denied, submit a formal written appeal with additional documentation. External independent review is available as a final step.

Does the Lilly savings card work with all insurance? No. The Lilly savings card works only with commercial insurance plans that already cover tirzepatide. It doesn't work for Medicare, Medicaid, TRICARE, VA, or uninsured patients. Kaiser Permanente doesn't accept manufacturer copay cards. The card reduces your copay, it doesn't create coverage.

What's the difference between Mounjaro and Zepbound coverage? Mounjaro (tirzepatide for diabetes) is covered by approximately 85% of commercial plans. Zepbound (tirzepatide for weight loss) is covered by approximately 25% of commercial plans. They contain the same medication but have different FDA approvals and different insurance coverage rules.

Does UnitedHealthcare cover tirzepatide for weight loss? Some UnitedHealthcare plans cover Zepbound for weight management with prior authorization requiring BMI ≥30 and documented comorbidities (cardiovascular disease, sleep apnea, or type 2 diabetes). Coverage depends on your specific employer's plan design. Check your formulary or contact UnitedHealthcare directly.

How long does prior authorization take for tirzepatide? Standard prior authorization decisions take 3 to 14 business days depending on the insurance company. Expedited PA for urgent situations takes 24 to 72 hours. Average approval rate on first submission is 62% for diabetes and 31% for weight loss.

Is compounded tirzepatide covered by insurance? No. Compounded medications are not covered by insurance because they're not FDA-approved products. Compounded tirzepatide costs $179 to $499 per month paid out of pocket, often cheaper than brand-name insurance copays for patients with high deductibles or specialty tier placement.

Sources

1. Lilly USA. Mounjaro Prescribing Information. Updated 2024.
2. Lilly USA. Zepbound Prescribing Information. Updated 2024.
3. IQVIA Institute for Human Data Science. Prior Authorization Trends in Specialty Medications. 2025.
4. Kaiser Family Foundation. Employer Health Benefits Survey. 2025.
5. Mercer. National Survey of Employer-Sponsored Health Plans. 2025.
6. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Analysis. 2026.
7. America's Health Insurance Plans (AHIP). Prior Authorization and Appeals Data. 2025.
8. Diabetes Leadership Council. GLP-1 Receptor Agonist Formulary Tier Placement Study. 2025.
9. National Association of Insurance Commissioners. External Review Data. 2025.
10. U.S. Census Bureau. Health Insurance Coverage Statistics. 2025.
11. Lilly Investor Relations. Q4 2025 Earnings Call Transcript. February 2026.
12. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Public Law 108-173.
13. Nissen SE et al. Cardiovascular Safety of Tirzepatide in Patients With Type 2 Diabetes: SURPASS-CVOT. Circulation. 2024.
14. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Blue Cross Blue Shield, UnitedHealthcare, Aetna, Cigna, Humana, Anthem, and Kaiser Permanente are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.